Daraxonrasib Approved for Metastatic Pancreatic Cancer
Key Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Points Summary An international expert group has created the first consensus definition for oligometastatic pancreatic cancer. The OligoPanc project,
Read More